Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16635439 | 0.81 | TRPA1 (0.40) | NPC1RAB9ATRPA1TSHR | |
| SCHEMBL16634867 | 0.75 | TRPA1 (0.47) | TRPA1SRCBRAFKDRNOTUM | |
| SCHEMBL16634906 | 0.75 | TRPA1 (0.49) | NPC1RAB9ATRPA1TSHRSRC | |
| SCHEMBL16635554 | 0.75 | KMT2A (0.43) | RAB9ATRPA1SRCBRAFKDR | |
| SCHEMBL17973851 | 0.74 | TRPA1 (0.44) | TRPA1NOTUMADORA3AADAT | |
| SCHEMBL16635038 | 0.73 | CA12 (0.44) | TRPA1NOTUMMAPKAPK2AADAT | |
| SCHEMBL16647989 | 0.72 | MEN1 (0.46) | TRPA1SRCBRAFKDRNOTUM | |
| SCHEMBL17959536 | 0.72 | MEN1 (0.46) | TRPA1SRCBRAFKDRNOTUM | |
| SCHEMBL20577700 | 0.69 | KIF11 (0.45) | NPC1RAB9AKIF11NPSR1 | |
| SCHEMBL29615293 | 0.69 | KIF11 (0.45) | NPC1RAB9AKIF11NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3487853-B1 | BICYCLIC PROLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| CN-109476640-B | Bicyclic proline compounds | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-10597383-B2 | Bicyclic proline compounds | GENENTECH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20190144428-A1 | BICYCLIC PROLINE COMPOUNDS | GENENTECH, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3055302-B1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | NPC1 1385/4885RAB9A 2664/4885TRPA1 1/4885 |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | NPC1 1385/4885RAB9A 2664/4885TRPA1 1/4885 |
| US-10597383-B2 | Bicyclic proline compounds | TRPA1, TRPV1, TRPV5 | NPC1 502/4885RAB9A 3026/4885TRPA1 1/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | NPC1 1385/4885RAB9A 2664/4885TRPA1 1/4885 |
| US-20190144428-A1 | BICYCLIC PROLINE COMPOUNDS | TRPA1, TRPV1, TRPV5 | NPC1 502/4885RAB9A 3026/4885TRPA1 1/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | NPC1 1385/4885RAB9A 2664/4885TRPA1 1/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | NPC1 1385/4885RAB9A 2664/4885TRPA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.